Agreed, but it was a failure at an artificially high price that was kept high so as to not erode profit margin on what Braeburn believed would be their cash cow (injectables). A distributor/licensee with no other fish in the fire in the buprenorphine market will hopefully be motivated to sell, and lower the price accordingly. If not, Titan may be capable of coming to deals with the VA, prison systems, state medicare plans, etc. that don't require a sales force.